Xilio Therapeutics (XLO) announced plans to present initial data from its ongoing Phase 2 trial for vilastobart, a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal cancer at the ASCO Gastrointestinal Cancers Symposium in San Francisco, California from January 23-25, 2025. In addition, today the company announced preliminary data from Phase 1 dose escalation for XTX301, an investigational tumor-activated IL-12. Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XLO:
- Xilio Therapeutics appoints Caroline Hensley as CLO
- Xilio Therapeutics Reports Q3 2024 Progress and Financials
- Xilio Therapeutics Advances Cancer Drug and Financial Outlook
- Xilio Therapeutics announces initial data from Phase 1C trial for XTX101
- Xilio Therapeutics expects cash to fund operations into Q2 of 2025